XORTX Therapeutics (NASDAQ:XRTX) Announces Quarterly Earnings Results

XORTX Therapeutics (NASDAQ:XRTX) issued its earnings results on Friday. The technology company reported ($0.21) EPS for the quarter, FiscalAI reports.

XORTX Therapeutics Stock Up 19.6%

Shares of NASDAQ:XRTX traded up $0.18 during trading on Friday, hitting $1.10. 1,586,112 shares of the company were exchanged, compared to its average volume of 71,803. XORTX Therapeutics has a 1-year low of $0.82 and a 1-year high of $3.60. The company has a market capitalization of $2.00 million, a P/E ratio of -0.40 and a beta of 0.83. The business’s 50 day moving average is $1.47 and its 200-day moving average is $2.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XORTX Therapeutics in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, XORTX Therapeutics has an average rating of “Sell”.

XORTX Therapeutics Company Profile

XORTX Therapeutics Inc. (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases. XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function.